Revenue
2019
2020
2021
2022
2023
2024
2025
Pharming Group N.V. (PHAR)
Price$10.81Cached quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $376.1M | $297.2M | $245.3M | $205.6M | $198.9M | $212.2M | $189.4M | — |
| Gross profit | $330.6M | $261.8M | $220.1M | $188.1M | $177.7M | $188.6M | $165.5M | — |
| Gross margin | 87.90% | 88.09% | 89.72% | 91.46% | 89.37% | 88.91% | 87.37% | — |
| Research & development | $100.4M | $83.1M | $68.9M | $52.5M | $70.4M | $38.5M | $31.8M | — |
| Operating expenses | $304.8M | $270.4M | $225.5M | $169.8M | $164.2M | $112.4M | $97.2M | — |
| Operating income | $25.8M | −$8.6M | −$5.4M | $18.2M | $13.6M | $76.3M | $68.2M | — |
| Operating margin | 6.87% | −2.90% | −2.20% | 8.87% | 6.82% | 35.94% | 36.03% | — |
| EBITDA | $33.8M | −$848,000 | $2.0M | $24.1M | $20.0M | $82.3M | $73.2M | — |
| EBITDA margin | 8.98% | −0.29% | 0.81% | 11.74% | 10.03% | 38.79% | 38.67% | — |
| Net income | $2.5M | −$11.8M | −$10.5M | $13.7M | $16.0M | $37.7M | $40.6M | — |
| Net profit margin | 0.67% | −3.98% | −4.30% | 6.65% | 8.04% | 17.79% | 21.41% | — |
| Basic EPSper basic share | $0.00 | -$0.02 | -$0.02 | $0.02 | $0.03 | $0.06 | $0.07 | — |
| Diluted EPSper diluted share | $0.00 | -$0.02 | -$0.02 | $0.02 | $0.02 | $0.06 | $0.06 | — |
Insider buys & sells
Community posts
Pharming expands Joenja approval to younger children with APDS
Pharming ($PHAR) secured FDA approval to use Joenja in children aged four to 11 with activated PI3K delta syndrome who weigh at least 27 kilograms. The expansion adds younger patients to the medicine’s existing indication for older patients ...